SCM
HELP

Silverarc Capital Management’s Helus Pharma Inc. Common Stock HELP Stock Holding History

Silverarc Capital Management’s Portfolio HELP Stock Details HELP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,579
Closed -$549K – 78
2021
Q3 		$549K Buy
+6,579
New +$576K 0.31% 65

Other funds holding HELP

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCC
Perry Creek Capital New York $218M AUM 18.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
CCG
Ceeto Capital Group Coral Gables, Florida $369M AUM 34.8% 1-Year Est. Return
T
TCWP Beachwood, Ohio $40.8M AUM 31.25% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Silverarc Capital Management's HELP Position: Q4 2021 in Review

Silverarc Capital Management sold out of Helus Pharma Inc. Common Stock (HELP) in Q4 2021, closing a stake of 6,579 shares — an estimated $549K sold.

Silverarc Capital Management first reported a position in HELP in Q3 2021 and held it in 1 quarter. The position peaked at $549K in Q3 2021. 65 funds tracked by Wall St. Rank hold HELP as of Q4 2021.

  • Silverarc Capital Management reported no remaining Helus Pharma Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 6,579 Helus Pharma Inc. Common Stock shares in Q4 2021, an estimated $549K.
  • Silverarc Capital Management first reported a position in Helus Pharma Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Silverarc Capital Management's Helus Pharma Inc. Common Stock position peaked at $549K in Q3 2021.
  • 65 funds tracked by Wall St. Rank held Helus Pharma Inc. Common Stock as of Q4 2021.

Based on Silverarc Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.